Two ADAURA analyses support use of Osimertinib for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer

(Singapore–16:45 p.m. SPT/3:45 EST January 29, 2021)–Two presentations from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival (DFS) outcomes for patients with surgically resected non-small cell lung cancer (NSCLC) receiving osimertinib. The data were reported today at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung…

Automated AI algorithm uses routine imaging to predict cardiovascular risk

Coronary artery calcification — the buildup of calcified plaque in the walls of the heart’s arteries — is an important predictor of adverse cardiovascular events like heart attacks. Coronary calcium can be detected by computed tomography (CT) scans, but quantifying the amount of plaque requires radiological expertise, time and specialized equipment. In practice, even though…

Remdesivir disrupts COVID-19 virus better than other similar drugs

In the treatment of SARS-CoV-2, the virus that causes COVID-19, antiviral drug remdesivir has emerged as a promising candidate. Remdesivir works by disrupting the virus’s ability to replicate, but its exact mechanism has remained a mystery. Using advanced computational simulations, researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago have…